Clinical Study
Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2
Table 2
Factors associated with response to peginterferon alfa-2b and ribavirin therapy.
| | | SVR | (Range or %) | Non-SVR | (Range or %) | value |
| | Total | 74 | | 26 | | | | Age (y.o.) | 57 | (24–72) | 57 | (31–78) | NS | | Sex (%) | | | | | | | Male | 33 | (45) | 13 | (50) | | | Female | 41 | (55) | 13 | (50) | NS | | BMI (kg/m2) | 23.1 | (15.4–30.9) | 21.0 | (18.4–26.0) | NS | | WBC (/L) | 5100 | (2100–9730) | 5145 | (3000–8300) | NS | | Hemoglobin (g/dL) | 14.1 | (10–16) | 14.0 | (10–16) | NS | | Platelet (104/L) | 21.7 | (6.9–26.5) | 11.5 | (7.3–21.1) | NS | | AST (IU/L) | 39 | (17–377) | 44 | (17–140) | NS | | ALT (IU/L) | 51 | (11–751) | 53 | (14–169) | NS | | TC (mg/dL) | 183 | (106–269) | 163 | (127–248) | NS | | 177 mg/dL (%) | 31 | (42) | 19 | (73) | | | 177 mg/dL (%) | 43 | (58) | 7 | (27) | 0.005 | | TG (mg/dL) | 98 | (56–262) | 83 | (74–176) | NS | | <88 mg/dL (%) | 33 | (44) | 17 | (67) | | | 88 mg/dL (%) | 41 | (56) | 9 | (33) | NS | | LDL-C (mg/dL) | 109 | (30–167) | 88 | (64–117) | 0.015 | | 98 mg/dL (%) | 30 | (40) | 20 | (77) | | | 98 mg/dL (%) | 44 | (60) | 6 | (23) | 0.020 | | HCV RNA (KIU/mL) | 1000 | (20–40900) | 1850 | (37–24200) | NS | | Distribution of stage of fibrosis (%) | | | | | | | 1 | 31 | (42) | 12 | (46) | | | 2 | 14 | (19) | 3 | (12) | | | 3 | 6 | (8) | 5 | (19) | | | 4 | 3 | (4) | 1 | (4) | | | Unknown | 20 | (27) | 5 | (19) | NS | | Distribution of grade of inflammation (%) | | | | | | | 1 | 27 | (36) | 12 | (46) | | | 2 | 25 | (34) | 9 | (35) | | | 3 | 2 | (3) | 0 | (0) | | | Unknown | 20 | (27) | 5 | (19) | NS |
|
|
Data are median (range) or frequency (%).
|
